Get the Stockscreener App
10.97
0.99%
-0.11
After Hours:
10.97
Immunome Inc stock is traded at $10.97, with a volume of 1.42M.
It is down -0.99% in the last 24 hours and up +17.58% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
See More
Previous Close:
$11.08
Open:
$10.94
24h Volume:
1.42M
Relative Volume:
1.81
Market Cap:
$684.71M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-4.9864
EPS:
-2.2
Net Cash Flow:
$-8.40M
1W Performance:
-12.80%
1M Performance:
+17.58%
6M Performance:
-12.80%
1Y Performance:
+32.97%
1-Day Range:
$10.82
$11.50
1-Week Range:
$10.76
$12.85
52-Week Range:
$8.15
$30.96
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
10.97 | 684.71M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome, Inc. (NASDAQ:IMNM) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from Analysts - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Wellington Management Group LLP - Defense World
Immunome, Inc. (NASDAQ:IMNM) Sees Significant Decrease in Short Interest - Defense World
Immunome, Inc. (NASDAQ:IMNM) Short Interest Update - MarketBeat
Long Term Trading Analysis for (IMNM) - Stock Traders Daily
Immunome, Inc. (NASDAQ:IMNM) Position Lifted by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome: A Recently Acquired Lead Asset And A Small Market (NASDAQ:IMNM) - Seeking Alpha
The Manufacturers Life Insurance Company Sells 1,437 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Intech Investment Management LLC Takes $219,000 Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Janus Henderson Group PLC Purchases 324,614 Shares of Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Cerity Partners LLC Has $776,000 Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Where are the Opportunities in (IMNM) - Stock Traders Daily
Immunome Grants Stock Options to 15 New Hires in Workforce Expansion - StockTitan
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference - The Bakersfield Californian
President of Immunome Picks Up 24% More Stock - Simply Wall St
Why Is Immunome Inc (NASDAQ: IMNM) Gaining? - Stocks Register
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts - Defense World
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity - Defense World
Immunome's chief medical officer Robert Lechleider buys $149,799 in stock - Investing.com India
Immunome's chief medical officer Robert Lechleider buys $149,799 in stock By Investing.com - Investing.com Australia
Immunome Inc (IMNM) CEO Clay Siegall Increases Stake with Signif - GuruFocus.com
Insider Buying: Robert Lechleider Acquires Shares of Immunome In - GuruFocus.com
Immunome, Inc. (NASDAQ:IMNM) CTO Acquires $198,030.00 in Stock - MarketBeat
Insider Buying: Immunome, Inc. (NASDAQ:IMNM) CEO Purchases 66,057 Shares of Stock - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Insider Acquires $149,831.40 in Stock - MarketBeat
Philip Tsai, CTO of Immunome, buys $198,030 in company stock By Investing.com - Investing.com South Africa
Philip Tsai, CTO of Immunome, buys $198,030 in company stock - Investing.com India
Immunome CEO Clay Siegall acquires $962,181 in company stock By Investing.com - Investing.com Nigeria
Immunome CEO Clay Siegall acquires $962,181 in company stock - Investing.com India
(IMNM) Investment Analysis and Advice - Stock Traders Daily
Immunome files to sell 1.8M shares of common stock for holders - TipRanks
Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Victory Capital Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for Immunome - MarketBeat
Wedbush Has Bullish Outlook for Immunome FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for Immunome Lowered by Leerink Partnrs - Defense World
Immunome Inc. Announces Third Quarter 2024 Financial Results and Pipeline Progress - Defense World
Stephens & Co. Initiates Coverage of Immunome (IMNM) with Overweight Recommendation - MSN
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Immunome (NASDAQ:IMNM) Stock Price Down 7% After Analyst Downgrade - Defense World
T. Rowe Price Investment Management, Inc. Expands Stake in Immun - GuruFocus.com
Piper Sandler maintains overweight on IMNM with $21 target By Investing.com - Investing.com Canada
Piper Sandler maintains overweight on IMNM with $21 target - Investing.com India
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Janus Henderson Group's Strategic Acquisition of Immunome Inc Sh - GuruFocus.com
Immunome (NASDAQ:IMNM) Shares Down 7% Following Analyst Downgrade - MarketBeat
Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00 - MarketBeat
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
| Tsai Philip | Chief Technology Officer |
Nov 21 '24 |
Buy |
9.43 |
21,000 |
198,030 |
21,000 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Option Exercise |
1.05 |
42,000 |
44,100 |
61,856 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Sale |
16.01 |
14,380 |
230,224 |
47,476 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):